Developer docs
API playgroundTry for free, no card

Search company profiles

Valink Therapeutics

Full company profile

uuid0003w8s

Namestring
Valink Therapeutics
Legal namestring
Valink Therapeutics Inc.
Websiteurl
valinktx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Valink Therapeutics is a preclinical biopharmaceutical company developing bispecific antibody-drug conjugates (bsADCs) and complementary multimodal ADC technologies for solid tumor indications including colorectal cancer and non-small cell lung cancer. Founded in 2021 as LiliumX and rebranded in November 2023, the company is a spinout from the University of Oxford's Department of Biochemistry and holds licenses to foundational protein conjugation IP including the SpyTag/SpyCatcher system.

The company's core asset is the LiliumX discovery platform, a proprietary engine built on three pillars: synthetic protein biology, high-throughput functional screening (1,000+ candidates/week with a one-week design-to-screen turnaround), and AI-driven molecular design over curated disease datasets. This platform underpins the company's V-Gate targeting approach, which moves beyond conventional AND-GATE/OR-GATE bispecific logic to enable continuous, fine-tuned target control. Valink is advancing four oncology programs (VLN1–VLN4) through discovery and lead optimisation.

Valink operates a capital-efficient, partnership-oriented business model: it is venture-backed (cumulative ~$19.9M raised across Y Combinator, a 2023 seed led by RV Invest, and a 2025 Pre-A led by redalpine), employs 21 people across a US headquarters in Cambridge, Massachusetts and an R&D subsidiary in London, and generates no commercial product revenue today. Its intended monetization paths are licensing deals, co-development partnerships (exemplified by the December 2025 'Biology to Bispecific' alliance with Nona Biosciences), and eventual out-licensing or commercialization of preclinical assets to larger pharmaceutical companies.

Short descriptiontext

Valink Therapeutics is a preclinical biopharmaceutical company developing bispecific antibody-drug conjugates for solid tumors using its proprietary LiliumX discovery platform and V-Gate targeting approach, targeting pharmaceutical partners for future co-development and licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibody-drug conjugates, oncology therapeutics, drug discovery platform, cancer biologics, preclinical ADC development
Industry4 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bispecific Antibody-Drug Conjugates (Oncology Therapeutics)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pipeline Development and Licensing
TypeLicensing Royalties
Description

Valink Therapeutics is developing a pipeline of bispecific antibody-drug conjugates for oncology applications. The company is in the preclinical development stage with two oncology programs. Revenue generation will likely come from licensing deals, co-development partnerships, or eventual commercialization of therapeutic candidates.

valinktx.com
2Platform Technology Partnerships
TypeProfessional Services
Description

The company leverages its LiliumX discovery platform to forge strategic alliances with other biotech and pharma companies for collaborative drug discovery and development, potentially generating partnership revenue and milestone payments.

valinktx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Valink Therapeutics develops bispecific antibody-drug conjugate (bsADC) therapeutics for solid tumor oncology using its proprietary LiliumX™ discovery platform. The company is advancing a preclinical pipeline of oncology programs (VLN1, VLN2, VLN3, VLN4) targeting colorectal cancer, NSCLC, and pan-cancer indications, with the V-Gate™ approach enabling fine-tuned, continuous-level target control beyond conventional binary gating. Commercial monetization is expected through licensing, co-development partnerships, and milestone/royalty arrangements with larger pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 1-week turnaround time from design to high-throughput screening experiments (1,000+/week)
+1 more record
Product overview1 text field

Valink Therapeutics is a biopharmaceutical company developing a portfolio of bispecific antibody-drug conjugates (bsADCs) and complementary modalities for oncology. The core of its offering is the LiliumX™ discovery platform, a proprietary high-throughput screening engine combining synthetic protein biology, automation, and AI. This platform powers the V-Gate™ targeting approach, which goes beyond conventional binary gating (AND-GATE, OR-GATE) to enable fine-tuned, continuous-level target control in bispecific ADCs. The company is advancing multiple oncology programs (VLN1, VLN2, VLN3, VLN4) through discovery and preclinical stages, initially focused on colorectal cancer, NSCLC, and other solid tumors. Beyond bsADCs, Valink has developed proprietary protein technologies for dual-payload conjugation, trispecific ADCs, and multivalent antibody platforms. A December 2025 strategic alliance with Nona Biosciences (branded 'Biology to Bispecific') further extends the LiliumX platform by combining it with Nona's Harbour Mice® antibody libraries for expanded bsADC candidate generation.

Product and service4 records
1LiliumX™ Discovery Platform
CategoryDrug discovery platform / technology
Description

Proprietary drug discovery engine combining synthetic protein biology, high-throughput functional screening, and AI to rapidly generate and screen bispecific antibody-drug conjugate candidates, with a 1-week design-to-screening turnaround and 1,000+ candidates/week throughput. Used internally by Valink and offered to partners through co-development alliances.

2V-Gate™ Bispecific ADC Targeting Approach
CategoryTherapeutic targeting technology / IP-backed approach
Description

Next-generation bispecific ADC targeting logic that enables continuous (non-binary) target engagement, allowing therapeutic binding to cancer cells to be tuned to the continuous levels of each target rather than mere presence/absence. Used within Valink's pipeline and as a differentiated IP-backed targeting concept in licensing discussions.

3Oncology Pipeline — VLN1, VLN2, VLN3, VLN4
CategoryBispecific antibody-drug conjugate pipeline / oncology assets
Description

Preclinical portfolio of bispecific antibody-drug conjugate programs targeting solid tumors, including an unannounced program, VLN1 (CRC, pan-cancer), VLN2 (CRC, lead optimisation/preclinical), VLN3 (NSCLC, solid tumors), and VLN4. Available for licensing, co-development, or partnership with pharmaceutical companies.

4Biology to Bispecific (B2B)™ Strategic Alliance with Nona Biosciences
CategoryBiologics discovery alliance / co-development offering
Description

Strategic alliance that combines Valink's LiliumX discovery platform with Nona Biosciences' Harbour Mice® fully human antibody technology (including heavy chain-only antibodies) to generate and screen thousands of novel bsADC candidates for solid tumors, supporting future co-development and licensing transactions.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-17
Description

Strategic biologics discovery alliance branded 'Biology to Bispecific' (B2B) combining Valink's LiliumX discovery platform with Nona's Harbour Mice antibody technology. The collaboration will generate and screen thousands of novel drug candidates initially focused on bispecific ADCs for solid tumors. The partnership aims to expand Valink's therapeutic pipeline and contribute to future co-development and licensing opportunities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-11-02
Description

Technology transfer partner from which LiliumX was spun out. Licenses world-class protein conjugation technologies including the SpyTag/SpyCatcher system. Valink is the first company in 24 years formed solely from Oxford's Department of Biochemistry.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-18
Description

Company originated from research conducted at the Department of Biochemistry at the University of Oxford. Founders Arne Scheu and Irsyad Khairil developed 'LEGO' protein technologies during their studies at Oxford.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Bispecific T cell engager biotech (acquired by Takeda). Valink's bispecific ADC work shares the same modular, condition-activated bispecific design philosophy targeting improved therapeutic index.

2Dragonfly Therapeutics
TypeEmerging player
Description

Developer of multispecific antibodies and cytokine-based therapeutics for cancer and autoimmune disease. Comparable multispecific platform approach; Alexey Lugovskoy was previously COO at Dragonfly.

TypeDirect peer
Description

Clinical-stage biotech developing multifunctional therapeutics including bispecific antibodies and ADCs (e.g., zanidatamab, zanidatamab-crowdr). Direct competitor in bispecific antibody engineering with established platform and partnerships.

4Alphina Therapeutics
TypeEmerging player
Description

Early-stage ADC-focused biotech where SAB member Marc Damelin serves as CSO. Comparable in stage and modality focus, and represents a peer for ADC talent and platform competition.

5Innate Pharma
TypeDirect peer
Description

Clinical-stage biotech using monoclonal antibodies, multi-specific NK cell engagers, and ADCs for cancer immunotherapy. SAB member Sonia Quaratino is Innate's CMO. Comparable in antibody and bispecific ADC development for oncology.

TypeEmerging player
Description

Clinical-stage biotech developing T cell engager immunotherapies using bispecific antibody technology (TRACTr platform). Comparable in novel bispecific architecture and oncology focus, though T cell engagers differ mechanistically from bsADCs.

TypeEmerging player
Description

AI-driven biologics platform company developing generative protein therapeutics, including ADCs and multispecifics. Comparable AI + protein biology discovery paradigm and early-stage pipeline orientation.

TypeDirect peer
Description

Clinical-stage ADC company developing ADCs for cancer using proprietary payload and linker platforms (e.g., Dolasynthen, Immunosynthen). Direct competitor in ADC development for oncology with SAB overlap (Marc Damelin was previously VP Biology at Mersana).

TypeDirect peer
Description

Biotech developing agonist antibodies and multispecific biologics, led by Alexey Lugovskoy (also a Valink board member/SAB). Overlap in bispecific and multispecific antibody design for serious diseases, including oncology.

TypeDirect peer
Description

Clinical-stage biotech developing ADCs and bispecific ADCs for solid tumors. Direct competitor in the bsADC space with overlapping science (Robert Lutz serves as CSO at Iksuda and is also on Valink's SAB), creating both competitive and informational overlap.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valink Therapeutics

Bispecific Antibody-Drug Conjugates (Oncology Therapeutics)valinktx.com

Valink Therapeutics is a preclinical biopharmaceutical company developing bispecific antibody-drug conjugates for solid tumors using its proprietary LiliumX discovery platform and V-Gate targeting approach, targeting pharmaceutical partners for future co-development and licensing.

What Valink Therapeutics does

Valink Therapeutics is a preclinical biopharmaceutical company developing bispecific antibody-drug conjugates (bsADCs) and complementary multimodal ADC technologies for solid tumor indications including colorectal cancer and non-small cell lung cancer. Founded in 2021 as LiliumX and rebranded in November 2023, the company is a spinout from the University of Oxford's Department of Biochemistry and holds licenses to foundational protein conjugation IP including the SpyTag/SpyCatcher system.

The company's core asset is the LiliumX discovery platform, a proprietary engine built on three pillars: synthetic protein biology, high-throughput functional screening (1,000+ candidates/week with a one-week design-to-screen turnaround), and AI-driven molecular design over curated disease datasets. This platform underpins the company's V-Gate targeting approach, which moves beyond conventional AND-GATE/OR-GATE bispecific logic to enable continuous, fine-tuned target control. Valink is advancing four oncology programs (VLN1–VLN4) through discovery and lead optimisation.

Valink operates a capital-efficient, partnership-oriented business model: it is venture-backed (cumulative ~$19.9M raised across Y Combinator, a 2023 seed led by RV Invest, and a 2025 Pre-A led by redalpine), employs 21 people across a US headquarters in Cambridge, Massachusetts and an R&D subsidiary in London, and generates no commercial product revenue today. Its intended monetization paths are licensing deals, co-development partnerships (exemplified by the December 2025 'Biology to Bispecific' alliance with Nona Biosciences), and eventual out-licensing or commercialization of preclinical assets to larger pharmaceutical companies.

Valink Therapeutics firmographics

Firmographics
Name
Valink Therapeutics
Legal name
Valink Therapeutics Inc.
Website
https://valinktx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Valink Therapeutics is a preclinical biopharmaceutical company developing bispecific antibody-drug conjugates for solid tumors using its proprietary LiliumX discovery platform and V-Gate targeting approach, targeting pharmaceutical partners for future co-development and licensing.
Ownership category
akta.pro rank

Valink Therapeutics industry classification

Industry
Product category
Bispecific Antibody-Drug Conjugates (Oncology Therapeutics)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Bispecific antibody-drug conjugates
  • Oncology therapeutics
  • Drug discovery platform
  • Cancer biologics
  • Preclinical ADC development

Where Valink Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Valink Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pipeline Development and Licensing: Valink Therapeutics is developing a pipeline of bispecific antibody-drug conjugates for oncology applications. The company is in the preclinical development stage with two oncology programs. Revenue generation will likely come from licensing deals, co-development partnerships, or eventual commercialization of therapeutic candidates.
  2. Platform Technology Partnerships: The company leverages its LiliumX discovery platform to forge strategic alliances with other biotech and pharma companies for collaborative drug discovery and development, potentially generating partnership revenue and milestone payments.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Valink Therapeutics product offering

Product offering

Core offering

Valink Therapeutics develops bispecific antibody-drug conjugate (bsADC) therapeutics for solid tumor oncology using its proprietary LiliumX™ discovery platform. The company is advancing a preclinical pipeline of oncology programs (VLN1, VLN2, VLN3, VLN4) targeting colorectal cancer, NSCLC, and pan-cancer indications, with the V-Gate™ approach enabling fine-tuned, continuous-level target control beyond conventional binary gating. Commercial monetization is expected through licensing, co-development partnerships, and milestone/royalty arrangements with larger pharmaceutical companies.

Product overview

Valink Therapeutics is a biopharmaceutical company developing a portfolio of bispecific antibody-drug conjugates (bsADCs) and complementary modalities for oncology. The core of its offering is the LiliumX™ discovery platform, a proprietary high-throughput screening engine combining synthetic protein biology, automation, and AI. This platform powers the V-Gate™ targeting approach, which goes beyond conventional binary gating (AND-GATE, OR-GATE) to enable fine-tuned, continuous-level target control in bispecific ADCs. The company is advancing multiple oncology programs (VLN1, VLN2, VLN3, VLN4) through discovery and preclinical stages, initially focused on colorectal cancer, NSCLC, and other solid tumors. Beyond bsADCs, Valink has developed proprietary protein technologies for dual-payload conjugation, trispecific ADCs, and multivalent antibody platforms. A December 2025 strategic alliance with Nona Biosciences (branded 'Biology to Bispecific') further extends the LiliumX platform by combining it with Nona's Harbour Mice® antibody libraries for expanded bsADC candidate generation.

Differentiator

Problem solved

Functional benefit

Products and services

  • LiliumX™ Discovery Platform Proprietary drug discovery engine combining synthetic protein biology, high-throughput functional screening, and AI to rapidly generate and screen bispecific antibody-drug conjugate candidates, with a 1-week design-to-screening turnaround and 1,000+ candidates/week throughput. Used internally by Valink and offered to partners through co-development alliances.
  • V-Gate™ Bispecific ADC Targeting Approach Next-generation bispecific ADC targeting logic that enables continuous (non-binary) target engagement, allowing therapeutic binding to cancer cells to be tuned to the continuous levels of each target rather than mere presence/absence. Used within Valink's pipeline and as a differentiated IP-backed targeting concept in licensing discussions.
  • Oncology Pipeline — VLN1, VLN2, VLN3, VLN4 Preclinical portfolio of bispecific antibody-drug conjugate programs targeting solid tumors, including an unannounced program, VLN1 (CRC, pan-cancer), VLN2 (CRC, lead optimisation/preclinical), VLN3 (NSCLC, solid tumors), and VLN4. Available for licensing, co-development, or partnership with pharmaceutical companies.
  • Biology to Bispecific (B2B)™ Strategic Alliance with Nona Biosciences Strategic alliance that combines Valink's LiliumX discovery platform with Nona Biosciences' Harbour Mice® fully human antibody technology (including heavy chain-only antibodies) to generate and screen thousands of novel bsADC candidates for solid tumors, supporting future co-development and licensing transactions.

Quantifiable outcome

  • 1-week turnaround time from design to high-throughput screening experiments (1,000+/week)
  • +1 more outcomes

Companies that use Valink Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Valink Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Valink Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Nona BiosciencescoreTechnology or Integration · 17 December 2025Strategic biologics discovery alliance branded 'Biology to Bispecific' (B2B) combining Valink's LiliumX discovery platform with Nona's Harbour Mice antibody technology. The collaboration will generate and screen thousands of novel drug candidates initially focused on bispecific ADCs for solid tumors. The partnership aims to expand Valink's therapeutic pipeline and contribute to future co-development and licensing opportunities.
  • Oxford University InnovationcoreTechnology or Integration · 2 November 2023Technology transfer partner from which LiliumX was spun out. Licenses world-class protein conjugation technologies including the SpyTag/SpyCatcher system. Valink is the first company in 24 years formed solely from Oxford's Department of Biochemistry.
  • University of OxfordcoreStrategic or Co-development Partner · 18 May 2021Company originated from research conducted at the Department of Biochemistry at the University of Oxford. Founders Arne Scheu and Irsyad Khairil developed 'LEGO' protein technologies during their studies at Oxford.

Scale indicators5 records

Recent moves10 records

Expansion highlights5 records

Valink Therapeutics competitors and assessment

Company assessment

Direct peers

  • Maverick Therapeutics: Bispecific T cell engager biotech (acquired by Takeda). Valink's bispecific ADC work shares the same modular, condition-activated bispecific design philosophy targeting improved therapeutic index.
  • Zymeworks: Clinical-stage biotech developing multifunctional therapeutics including bispecific antibodies and ADCs (e.g., zanidatamab, zanidatamab-crowdr). Direct competitor in bispecific antibody engineering with established platform and partnerships.
  • Innate Pharma: Clinical-stage biotech using monoclonal antibodies, multi-specific NK cell engagers, and ADCs for cancer immunotherapy. SAB member Sonia Quaratino is Innate's CMO. Comparable in antibody and bispecific ADC development for oncology.
  • Mersana Therapeutics: Clinical-stage ADC company developing ADCs for cancer using proprietary payload and linker platforms (e.g., Dolasynthen, Immunosynthen). Direct competitor in ADC development for oncology with SAB overlap (Marc Damelin was previously VP Biology at Mersana).
  • Diagonal Therapeutics: Biotech developing agonist antibodies and multispecific biologics, led by Alexey Lugovskoy (also a Valink board member/SAB). Overlap in bispecific and multispecific antibody design for serious diseases, including oncology.
  • Iksuda Therapeutics: Clinical-stage biotech developing ADCs and bispecific ADCs for solid tumors. Direct competitor in the bsADC space with overlapping science (Robert Lutz serves as CSO at Iksuda and is also on Valink's SAB), creating both competitive and informational overlap.

Emerging players

  • Dragonfly Therapeutics: Developer of multispecific antibodies and cytokine-based therapeutics for cancer and autoimmune disease. Comparable multispecific platform approach; Alexey Lugovskoy was previously COO at Dragonfly.
  • Alphina Therapeutics: Early-stage ADC-focused biotech where SAB member Marc Damelin serves as CSO. Comparable in stage and modality focus, and represents a peer for ADC talent and platform competition.
  • Janux Therapeutics: Clinical-stage biotech developing T cell engager immunotherapies using bispecific antibody technology (TRACTr platform). Comparable in novel bispecific architecture and oncology focus, though T cell engagers differ mechanistically from bsADCs.
  • Generate Biomedicines: AI-driven biologics platform company developing generative protein therapeutics, including ADCs and multispecifics. Comparable AI + protein biology discovery paradigm and early-stage pipeline orientation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Valink Therapeutics social profiles

Digital presence

Valink Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valink Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Valink Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valink Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valink Therapeutics

What does Valink Therapeutics do?

Valink Therapeutics develops bispecific antibody-drug conjugate (bsADC) therapeutics for solid tumor oncology using its proprietary LiliumX™ discovery platform. The company is advancing a preclinical pipeline of oncology programs (VLN1, VLN2, VLN3, VLN4) targeting colorectal cancer, NSCLC, and pan-cancer indications, with the V-Gate™ approach enabling fine-tuned, continuous-level target control beyond conventional binary gating. Commercial monetization is expected through licensing, co-development partnerships, and milestone/royalty arrangements with larger pharmaceutical companies.

Is Valink Therapeutics a public or private company?

Valink Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Valink Therapeutics founded?

Valink Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Valink Therapeutics based?

Valink Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Valink Therapeutics make money?

Two revenue lines are on record. Pipeline Development and Licensing is the primary driver. The others are platform Technology Partnerships.

Who are Valink Therapeutics's main competitors?

Direct peers on record are Maverick Therapeutics, Zymeworks, Innate Pharma, Mersana Therapeutics, Diagonal Therapeutics and Iksuda Therapeutics. Emerging players are Dragonfly Therapeutics, Alphina Therapeutics, Janux Therapeutics and Generate Biomedicines.

Does Valink Therapeutics have an API?

No public API is recorded for Valink Therapeutics.

What industry is Valink Therapeutics in?

Valink Therapeutics's product category is Bispecific Antibody-Drug Conjugates (Oncology Therapeutics). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogValink Therapeutics and Nona Biosciences Form Strategic Alliance to Accelerate Novel Biologics DiscoveryValink Therapeutics and Nona Biosciences announced a strategic alliance to accelerate biologics discovery, focusing on bispecific antibodies and ADCs in solid tumors. The collaboration will leverage Valink’s LiliumX platform and Nona’s Harbour Mice antibodies to generate and screen novel drug candidates.PharmiWeb.comValink Therapeutics and Nona Biosciences Form Strategic Alliance to Accelerate Novel Biologics DiscoveryValink Therapeutics and Nona Biosciences have formed a strategic biologics discovery alliance called "Biology to Bispecific" (B2B) to develop bispecific antibodies and bispecific antibody-drug conjugates (bsADCs) for solid tumors. The collaboration combines Valink's LiliumX discovery platform with Nona's Harbour Mice fully human antibody technology to generate and screen thousands of novel drug candidates. The alliance aims to expand Valink's therapeutic pipeline and create future co-development and licensing opportunities in oncology.PR NewswireNona Biosciences and Valink Therapeutics Form Strategic Alliance to Accelerate Novel Biologics DiscoveryNona Biosciences and Valink Therapeutics announced a strategic biologics discovery alliance called "Biology to Bispecific" (B2B)™, combining Nona's Harbour Mice® human antibody platforms with Valink's LiliumX™ discovery platform to generate and screen thousands of novel bispecific antibody and bispecific ADC drug candidates. The collaboration will initially focus on solid tumors, with the goal of expanding Valink's internal therapeutic pipeline and creating future co-development and licensing opportunities. Nona Biosciences has previously supported over 300 drug discovery programs, while Valink is advancing two oncology programs into preclinical development for solid tumor indications including colorectal cancer.Pulse 2.0Valink Therapeutics: $11.8 Million Raised To Advance Bispecific ADC Pipeline And Expand U.S. OperationsValink Therapeutics closed an $11.8 million pre-A financing round led by redalpine, with participation from new investors LongeVC and Oxford Science Enterprises, along with existing backers RV Invest, p53 Invest, and Hoxton Ventures. The funding will advance the company's bispecific antibody-drug conjugate (bsADC) pipeline and support the establishment of new U.S. headquarters in Cambridge, Massachusetts. The company is advancing two oncology programs into preclinical development using its proprietary V-gate technology platform.BioSpaceValink Therapeutics Closes $11.8 Million Pre-A Financing Round to Advance Oncology PipelineValink Therapeutics announced the closure of an $11.8 million funding round to develop its oncology pipeline, focusing on bispecific antibody-drug conjugates (bsADCs) and other modalities. The funding will support the advancement of two oncology programs into preclinical development for solid tumor indications, including colorectal cancer.ValinktxPress Release: Valink Therapeutics Closes $11.8 Million Pre-A Financing Round to Advance Oncology PipelineValink Therapeutics Inc., a private biotechnology company developing bispecific antibody-drug conjugates for oncology, announced the closing of an $11.8 million Pre-A financing round on October 20, 2025. The funding was led by European venture capital firm redalpine, with participation from new investors LongeVC and Oxford Science Enterprises, as well as existing investors including RV Invest, Hoxton Ventures, and Oxonian Ventures. Proceeds will advance Valink's pipeline of first-in-class cancer treatments and support the company's expansion of its U.S. presence with headquarters in Cambridge, Massachusetts, alongside its R&D subsidiary in the United Kingdom.Business Wire BlogValink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory BoardValink Therapeutics appointed Martin D. Williams as chair of its board and named a scientific advisory board. Williams brings over 35 years of biopharmaceutical experience, including closing more than $5 billion in transactions. The board includes experts in ADC and bispecific therapeutics.